Skip to content

Rosuvastatin safe and effective treatment for elevated lipids caused by PIs

Duration of ddI treatment and dose risk factors for CD4 loss in patients taking ddI/tenofovir

Lipid-lowering drugs better at lowering blood fats caused by protease inhibitors than switching to NNRTI

Lipid-lowering drugs more effective than switch to NNRTI in managing lipid elevations

Replacement of protease inhibitor results in improved blood fat levels, but doesn't stop fat loss

Traditional risk factors, not PIs or HIV cause hardening of arteries in US study

Response to HAART improves due to better drugs and more expertise in their use

BMJ editorial: assess cardiovascular risk and consider delaying HAART until CD4s reach 200 cells/mm3

Stevens-Johnson syndrome affects mother and son taking nevirapine